Skip to main content
Rapid Dose Therapeutics Corp logo

Rapid Dose Therapeutics Corp — Investor Relations & Filings

Ticker · DOSE ISIN · CA75339A1012 CSE Manufacturing
Open in API
Filings indexed 490 across all filing types
Latest filing 2021-03-15 Merger & Acquisition
Country CA Canada
Listing CSE DOSE

About Rapid Dose Therapeutics Corp

https://rapid-dose.com/

Rapid Dose Therapeutics Corp. is a pharma-technology company specializing in proprietary drug delivery technologies engineered to enhance patient outcomes and quality of life. The core business revolves around an innovative oral delivery platform utilizing sublingual thin film strip technology. The company's flagship product, QuickStrip™, is a fast-dissolving system designed for the rapid release of pharmaceuticals, micronized oils, and over-the-counter medicines. QuickStrip™ is distinguished by its ability to achieve blood concentrations comparable to intravenous injection, offering superior bioavailability and rapid onset. RDT provides product innovation, production, and consultation services to the pharmaceutical and healthcare manufacturing sectors for both prescription and non-prescription applications.

Recent filings

Filing Released Lang Actions
Material document(s).pdf
Merger & Acquisition Classification · 100% confidence The document is titled 'AMALGAMATION AGREEMENT' and contains detailed articles and sections typical of a legal contract related to the amalgamation (merger) of companies. It includes terms such as 'Valuation', 'Representations and Warranties', 'Conditions Precedent', 'Closing', and 'Conduct of Business', which are standard in merger agreements. There is no indication that this is a financial report, earnings release, or regulatory filing. Instead, it is a formal agreement related to a merger transaction. Therefore, the document fits best under the category of Merger & Acquisition (MA). The document length and content confirm it is the actual agreement, not just an announcement or summary.
2021-03-15 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a production agreement between Rapid Dose Therapeutics and OG Laboratories to produce cannabis vape and CBD products. It contains no financial statements, no regulatory form references, no voting results, no management or board changes, no earnings data, and no detailed financial or operational report. It is a corporate announcement about a business partnership and production agreement. The document length is 6672 characters, which is sufficient for a detailed announcement but does not contain financial report content. Therefore, it fits best under the category of a general regulatory announcement or corporate news that does not fit other specific categories. According to the classification rules, such announcements fall under Regulatory Filings (RNS).
2021-03-10 English
News release - English.pdf
Regulatory Filings
2021-03-08 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a FORM 52-109FV2 Certification of Interim Filings for a venture issuer, signed by the CEO. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ending November 30, 2020. The content is primarily an officer certification letter confirming the accuracy and completeness of the interim filings, without containing actual financial data or substantive financial analysis. According to the CERTIFICATION RULE, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself. The document length is under 5,000 characters and it is a certification, not the report or announcement of a report. Therefore, the correct classification is Regulatory Filings (RNS).
2021-01-29 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification statement by the Interim CFO regarding the review and fair presentation of the interim financial report and interim MD&A for the period ended November 30, 2020. It is a Form 52-109FV2 certification, which is a regulatory attestation related to interim filings. The document does not contain actual financial data or substantive financial analysis but rather certifies the accuracy and completeness of the interim filings. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is short (2957 characters), and it is clearly a certification letter, not the interim report or MD&A itself.
2021-01-29 English
Interim MD&A - English.pdf
Management Reports Classification · 95% confidence The document is titled "Management's Discussion and Analysis November 30, 2020" and contains detailed discussion and analysis of the financial condition and results of operations for the 9 months ended November 30, 2020. It includes forward-looking statements, overall performance, revenue details, capital transactions, and agreements. The content is consistent with a Management Discussion and Analysis (MD&A) report, which is a detailed explanation of financial results and business trends. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. There is no indication that this is an Annual Report (10-K), Audit Report, or Earnings Release. It is not a presentation or a proxy statement. Therefore, the most appropriate classification is Management Reports (MDA).
2021-01-29 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.